EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Cobalt(III) Schiff Base Complexes as Irreversible Inhibitors of the Metallo-β-Lactamase NDM-1

Hendryck A. Gellineau, Addison M. Duda, Zachary J. Mast, Sarah S. Angle, Andrew D. Ladhani, Lin X. Chen, Katherine J. Franz, Thomas J. Meade

ACS Infectious Diseases · 2026-11-03

DOI: 10.1021/acsinfecdis.6c00433 ↗
AbstractBibliografische Angaben

Abstract

Abstract Antibiotic resistance is a critical public health concern, with approximately 2.8 million Americans infected with antibiotic-resistant bacteria annually and over 35,000 deaths in the United States alone. Of particular concern are Enterobacterales that express metallo-β-lactamases (MBLs), bacteria that cause nosocomial infections and exhibit resistance to most β-lactam drugs. The zinc-containing active sites of MBLs differ from those of serine β-lactamases, making current clinical inhibitors ineffective. No FDA-approved MBL inhibitors exist, leaving a critical gap in therapeutics for MBL-expressing Enterobacterales infections. Herein, we biochemically and spectroscopically demonstrate irreversible inhibition of the metallo-β-lactamase NDM-1 by a subset of cobalt(III) Schiff base complexes (Co(III)-sb). Crystallography and 59Co NMR experiments show that inactivation efficiency is dependent on axial and equatorial ligand identity. While Co(III)-sb exhibits NDM-1 inhibition, chemical modification is required to enable complexes to cross the Gram-negative envelope. These findings establish Co(III)-sb complexes as a novel scaffold for the development of MBL inhibitors.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →